


OTC Naloxone One Step Closer as Harm Reduction Therapeutics Initiates a Rolling Submission of its New Drug Application to U.S. FDA for RiVive™ for Emergency Treatment of Opioid Overdose

Harm Reduction Therapeutics Signs Commercial Supply Agreement for Fast Tracked Naloxone Nasal Spray to Reverse Opioid Overdoses

Harm Reduction Therapeutics Announces that its Naloxone Nasal Spray Met its Primary Endpoints in a Phase 1 Clinical Trial
